✨ Free AI Report
Cullinan Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cullinan Therapeutics, Inc.
Company Research

Cullinan Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Cullinan Therapeutics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Cash-rich clinical biotech with differentiated autoimmune and oncology programs positioned for multiple data readouts in 2026. Cullinan is a cash-rich clinical-stage biotech with great autoimmune and AML T-cell research with promising catalysts for 2026. The company has strong analyst support with a "Strong Buy" average rating and a 12-month.

What is Cullinan Therapeutics, Inc.'s industry? Cullinan Therapeutics, Inc. (cullinantherapeutics.com) operates in Biopharmaceuticals - Clinical-stage oncology and autoimmune therapeutics. AskCyborg classifies Cullinan Therapeutics, Inc. under Biopharmaceuticals - Clinical-stage oncology and autoimmune therapeutics in its company registry.

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer in the United States. The company believes in a future where people living with autoimmune di...

7/ 10Strong

Cyborg Score thesis

Cash-rich clinical biotech with differentiated autoimmune and oncology programs positioned for multiple data readouts in...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Clinical-stage oncology and autoimmune therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cullinan Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Cullinan Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Cullinan Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cullinan Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Cullinan Therapeutics, Inc. Overview

Pro stress-test →

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer in the United States. The company believes in a future where people living with autoimmune diseases and cancer spend less time managing their conditions, with a clinical-stage pipeline reflecting a deliberate approach of advancing only the most promising molecules to address high unmet needs.

Strategic Profile

Pro stress-test →

The company is committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline. Strategic partnerships include collaboration with Adimab, LLC for antibody discovery and optimization, and a co-development agreement with Taiho Pharmaceutical Co., Ltd for zipalertinib.

Competitive Landscape

Pro stress-test →

Primary competitors include ORIC Pharmaceuticals, Aura Biosciences, Sorrento Therapeutics, Xenetic Bioscience, and Arcus Biosciences. Cullinan differentiates through its dual focus on autoimmune diseases and oncology using modality-diverse platforms including T cell engagers, small molecules, and monoclonal antibodies.

Industry Context

Cullinan Therapeutics, Inc. operates in Biopharmaceuticals - Clinical-stage oncology and autoimmune therapeutics.

Key facts

Founded: 2016 · Headquarters: Cambridge, Massachusetts · Market cap: $820M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cullinan Therapeutics, Inc..

  • Two high-priority investigational T cell engager programs, CLN-978 and CLN-049, position the company for a transformative year ahead.
  • Zipalertinib is in Phase 3 trial for treatment of non-small cell lung cancer patients with a co-development partner.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Announced initial CLN-049 results and development strategy for AML applications
  • Dec 2025Phase 1 data showed CLN-049 demonstrates approximately 30% complete response rate in heavily pretreated relapsed/refractory AML patients
  • +1 moreTrack every material event for Cullinan Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Cullinan Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Cancer and immunotherapy programsClinical-stage oncology company→Cancer and immunotherapy programsOncology-focused biopharmaceutical company→Autoimmune and oncology therapiesBiopharmaceutical development company→

Compare Cullinan Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cullinan Therapeutics, Inc. operates in Biopharmaceuticals - Clinical-stage oncology and autoimmune therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Clinical-stage oncology and autoimmune therapeutics research →
NEW · MCP server

Ask your AI assistant about Cullinan Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cullinan Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Cullinan Therapeutics, Inc. do this quarter?”
“Is Cullinan Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cullinan Therapeutics, Inc. do?+
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer in the United States. The company believes in a future where people living with autoimmune di...
What is Cullinan Therapeutics, Inc.'s Cyborg Score?+
Cullinan Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cullinan Therapeutics, Inc.'s main competitors?+
Named competitors include Cancer and immunotherapy programs, Cancer and immunotherapy programs, Autoimmune and oncology therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Cullinan Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cullinan Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cullinan Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Clinical-stage oncology and autoimmune therapeutics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Cullinan Therapeutics, Inc.